Search 

Mainstay is a unique venture-backed active implantable medical device company with a new proprietary device for treatment of people with chronic low back pain. Results from a European Feasibility Study developed very encouraging results.

Medxense offers accurate continuous glucose monitoring for the intensive care unit (ICU). Normalization of patient blood glucose allows hospitals to reduce mortality and patient length of stay. 

The patented sensor technology platform is the only in the field to offer both high accuracy and near-instantaneous measurements in the hypoglycemic range, necessary for safe normalization of blood glucose.

We are now looking for an investment of 3 MUSD to fund clinical trials in the 2nd half of 2014. Expected exits are trade sale or IPO.

TKS Technology A/S (TKS), a Danish registered limited company, specialized in developing and marketing wireless interface systems which create a whole new meaning to digital control, mobility and communication. 

Having spent 10 years and approx. EUR 2.5 million on research, development and testing by selected users TKS is now ready to bring the Itongue® product to market.

Itongue® is an intra-oral device which makes the user able to control devices with the tongue. The tongue is controlled directly by the brain - not through the spinal cord. Therefore Itongue® can be used by people suffering from severe paralysis not able to use traditional controllers. Furthermore, Itongue® does not only have a number of advantages compared to other applications, it simply takes controlling to the next generation. It is the only CE - certified control of its kind.

The intra-oral device is wirelessly connected to an external control unit which can be connected to control everything from computer keyboard and mouse to an electric wheelchair.

Based on the Itongue® platform TKS currently has planned 2 more innovative products in the pipeline. The first generation of Itongue® - now ready to be marketed - requires the user to get a tongue-piercing. The second generation – presently being developed - will not require a tongue piercing and will therefore be able to address a broader market such as surgeons, military jet pilots, gamers etc. Based on the current version of Itongue®. TKS is also developing a finger controlled version which is aimed at bringing better control capabilities to disabled who still have some movement capabilities in their fingers.

Having obtained a CE approval the Itongue® is now ready to be marketed as medical device in the EU.

Total global market which can be addressed by the Itongue® product is estimated to more than EUR 200 million annually with a split of approx. 40 per cent in Europe and 30 per cent in the US and with an expected growth rate of more than 100% per cent p.a.

Management of TKS expects to obtain some sales in 2013 and meet revenue objectives for 2014 of EUR 4 million, and in 2015 of EUR 10 million. Markets will be addressed through a combination of own sales force and external partners. Costumers for the first version of Itongue® are to be found among manufacturers of different types of medical devices e.g. wheelchairs.

The Company has now entered into a phase where the present owners and management are seeking a new owner / out-side co-investor who could add the required expertise and knowledge to commercialize the Company and its products - in other words to bring TKS and its products efficiently to the market; not only domestically but also in a number of international markets. An investment amount in the region of EUR 2 million is targeted in order to be able to full fill the business plan set up by the management of TKS. 

Basis organisation

Gert Spender, Exec. MBA, CEO 

Søren Mørch, M.Sc, development engineer (electronics) 

Jan Maltha, M.Sc. IT, development engineer (software) 

Poul Hansen, M.Sc. IT, development engineer (software) 

Hugo Bertelsen & Kirsten Berthelsen, interim technical project manager

Clinical trials partners and consultants

Lotte N.S. Andreasen Struijk, PhD (scientist and inventor), principal investigator 

Bo Bentsen (dentist) system encapsulation and materials

Dirk Leonhart (dental chief technician), Aarhus Dental College

Michael Gaihede, principal clinical investigator, Aalborg Hospital

Morten Haugland (reviewer), founder of Neurodan, currently scientific specialist of Medotech 

MediQA Consulting, Internal quality assurance and regulatory

DMD-Consulting, Poul Schmidt-Andersen, Managing Partner, B.Sc.E.E, B.Comm,

Compliance with EU and US regulatory requirements

Associated researchers

Lotte N.S. Andreasen Struijk, PhD, Associated Professor AAU

Fin Bering Sørensen, Professor dr. Med.

Eugen R. Lontis, PhD, development engineer (sensor technology design)

Hector A. Caltenco, PhD student (smart dictionary for the key pad)

Daniel Johansen, PhD student (SmartHand, control of hand prosthesis)

Brugerpanel (usergroup)